AI Screening for Diabetic Retinopathy
(DR-NeoRetina Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is the AI system for diabetic retinopathy screening safe for humans?
How is the treatment NeoRetina different from other treatments for diabetic retinopathy?
What data supports the effectiveness of the treatment NeoRetina, NeoRetina, CARA for diabetic retinopathy?
Who Is on the Research Team?
Karim Hammamji, MD
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Are You a Good Fit for This Trial?
This trial is for adults over 18 with diabetes (Type 1 for at least 5 years, or Type 2) who are being treated or referred by the CHUM hospital. They must be able to give informed consent. It's not suitable for those who don't meet these specific conditions.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
AI Screening and Ophthalmological Evaluation
Participants undergo screening for diabetic retinopathy using the NeoRetina AI algorithm and a full eye examination by an ophthalmologist
Follow-up
Participants are monitored for safety and effectiveness after the initial screening and evaluation
What Are the Treatments Tested in This Trial?
Interventions
- NeoRetina
NeoRetina is already approved in Canada, United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
DIAGNOS Inc.
Collaborator